ExeGi Pharma gets FDA orphan drug status for EXE-346 in pouchitis
ExeGi Pharma said that EXE-346 has been granted an orphan drug designation from the US Food and Drug Administration (FDA) for the prevention of disease relapse in pouchitis. EXE-346 is a live biotherapeutic (LBP) that contains a fixed-proportion of eight strains of live probiotic bacteria which are intended to be administered orally. Pouchitis is a […]